Strikingly the effect of Chk1 inhibition and cisplatin in FA deficient cell lines was synergistic, suggesting that Chk1 inhibitors may be useful for the treatment of tumours containing mutations of FA genes or in combination with novel FA pathway inhibitors. Here, CHEK1 is linked to neoplasm.